# Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder

> **NCT00969150** · PHASE3 · COMPLETED · sponsor: **Forest Laboratories** · enrollment: 362 (actual)

## Conditions studied

- Major Depressive Disorder

## Interventions

- **DRUG:** Levomilnacipran ER
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00969150
- **Lead sponsor:** Forest Laboratories
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-09
- **Primary completion:** 2010-11
- **Final completion:** —
- **Target enrollment:** 362 (ACTUAL)
- **Last updated:** 2013-10-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00969150

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00969150, "Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00969150. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*